Stryker Corp., US8636671013

Stryker stock holds growth targets despite cyber and market pressures

Published on 11/20/2026 at 14:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Stryker stock remains in focus as executives defend the company's long-term growth framework despite cyber and orthopedic pressures. Supply trends are improving.

Stryker maintains its long-term framework

  • Executives reiterated a target for adjusted operating-margin expansion over three years and annual free cash flow of 70% to 80%.
  • Management expects to recover cyberattack-related missed business during 2026, while Inari supply is stabilizing ahead of 2027.
  • A softer large-joint market is being offset by knee share gains and continued investment in robotics and hospital equipment.
Stryker Corp., US8636671013, Illustration mit AI erstellt.

Stryker executives reiterated the medical-device maker's long-term growth and profitability framework at the London Healthcare Conference, according to a MarketBeat report published via Yahoo Finance on Thursday, November 19, 2026. President and Chief Operating Officer Spencer Stiles, who is due to become chief executive in January, said Stryker continues to target growth at the high end of its markets.

The company still aims to expand adjusted operating margin by 150 basis points over three years and to generate annual free cash flow equal to 70% to 80% of adjusted net earnings, the report said. Chief Financial Officer Preston Wells indicated that efficiency measures could support the margin objective even if sales growth is slower, particularly during 2026.

Cyber disruption remains a 2026 issue

Management expects most effects from the cyberattack to remain concentrated in 2026. Stryker temporarily shut down operations while securing and restarting systems, with the most persistent supply disruption affecting Inari.

Inari supply has become more stable in the fourth quarter, and executives expect supply to meet demand as the business enters 2027. Wells said Stryker expects to recover in 2026 the business delayed by the cyberattack rather than carry those effects into 2027, although quarterly comparisons next year are likely to vary significantly.

Orthopedics and robotics set the priorities

Stiles said the U.S. large-joint hip and knee market is growing 2.5%, with economic pressure and some insurance denials leading patients to postpone procedures. Stryker is nevertheless gaining knee share at approximately 1.3 times the U.S. market rate in 2026, while management expects a gradual market recovery rather than an immediate rebound.

Hospital capital demand remains firm. Orders for beds and stretchers have lead times of six to nine months, while operating-room infrastructure projects can take one year to 18 months. Management said it had not seen order cancellations related to the cyberattack.

Acquisitions remain Stryker's preferred use of capital. The company has invested in soft-tissue robotics maker CMR Surgical and is building a U.S. sales channel for its Versius system, while retaining an option to acquire CMR later. Stryker is also evaluating opportunities in healthcare information technology, men's and women's health, soft-tissue robotics and neurotechnology.

Stock remains below the latest Xetra close

Stryker stock traded at 287.80 euros on Lang & Schwarz at 14:13 CET on Friday, November 20, 2026, 0.60% below the Xetra close of Wednesday, November 18, at 289.55 euros. The quote provides a current market reference while the company's operating priorities remain the central issue for investors.

Stryker Corporation

  • Company: Stryker Corporation
  • ISIN: US8636671013
  • Ticker: SYK
  • Primary listing: New York Stock Exchange
  • Lang & Schwarz quote: 287.80 euros at 14:13 CET on November 20, 2026
  • Xetra close: 289.55 euros on November 18, 2026

U.S. large-cap medical-device shares remain part of the broader S&P 500 market environment; investors can follow the S&P 500.

More news and analyses on Stryker stock

Disclaimer...
en | US8636671013 | STRYKER CORP. | boerse | 70540115 | bgmi